Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/121551

In Collections

This item can be found in the following collections:

Diavatopoulos, D.A.; Mills, K.H.G.; Kester, K.E.; Kampmann, B.; Silerova, M.; Heininger, U.; ... ; PERISCOPE Consortium (2019)

PERISCOPE: road towards effective control of pertussis

Article / Letter to editor
The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe ( PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel,...Show moreThe resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe ( PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.Show less
All authors
Diavatopoulos, D.A.; Mills, K.H.G.; Kester, K.E.; Kampmann, B.; Silerova, M.; Heininger, U.; Dongen, J.J.M. van; Most, R.G. van der; Huijnen, M.A.; Siena, E.; Mielcarek, N.; Ochs, M.M.; Denoel, P.; Berbers, G.; Buisman, A.M.; Jonge, M.I. de; Fenwick, C.; Gorringe, A.; He, Q.S.; Kelly, D.; Grand, R. le; Locht, C.; Mascart, F.; Mertsola, J.; Orfao, A.; Pantaleo, G.; Pollard, A.J.; Preston, A.; Read, R.; Sebo, P.; Els, C. van; Vecerek, B.; Londono-Hayes, P.; Groot, R. de; PERISCOPE Consortium
Date
2019-05-01
Journal
The Lancet Infectious Diseases
Volume
19
Issue
5
Pages
E179 - E186
DOI
doi:10.1016/S1473-3099(18)30646-7